Maria Luisa Garrè Selected Research

Maria Luisa Garrè Research Topics

Disease

25	Neoplasms (Cancer) 06/2022 - 04/2004
13	Glioma (Gliomas) 01/2020 - 04/2012
8	Ependymoma 12/2022 - 03/2008
7	Brain Neoplasms (Brain Tumor) 03/2020 - 09/2012
7	Medulloblastoma 10/2019 - 06/2007
3	Craniopharyngioma (Craniopharyngiomas) 01/2020 - 08/2007
3	Germinoma 01/2020 - 06/2013
3	Astrocytoma (Pilocytic Astrocytoma) 01/2016 - 09/2012
3	Neoplasm Metastasis (Metastasis) 09/2015 - 04/2004
2	Disease Progression 03/2020 - 05/2014
2	Glioblastoma (Glioblastoma Multiforme) 03/2015 - 09/2012
2	Neutropenia 10/2011 - 11/2007
2	Febrile Neutropenia 10/2011 - 11/2007
2	Familial ependymoma 08/2006 - 04/2004
1	Dyslipidemias (Dyslipidemia) 05/2022
1	Inflammation (Inflammations) 12/2021
1	Typical Teratoid Rhabdoid Tumor 01/2021
1	Ring Chromosomes (Ring Chromosome) 01/2021
1	Telomeric 22q13 Monosomy Syndrome 01/2021
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2020
1	COVID-19 01/2020
1	Hypophysitis 01/2020
1	Moyamoya Disease (Moya-Moya Disease) 03/2019
1	Chordoma 03/2019
1	Choroid Plexus Papilloma 09/2017
1	Heterotopic Ossification (Ectopic Ossification) 11/2015
1	Lymphedema (Milroy Disease) 09/2014
1	Lymphangitis 09/2014
1	Tuberous Sclerosis (Bourneville's Disease) 09/2014
1	Primitive Neuroectodermal Tumors (PNET) 05/2014
1	Ganglioglioma 01/2013
1	Central Nervous System Neoplasms 10/2011
1	Fever (Fevers) 10/2011
1	Residual Neoplasm 07/2011
1	Pinealoma (Pineoblastoma) 05/2010
1	Rhabdoid Tumor (Rhabdoid Tumors) 04/2010
1	Monosomy 04/2010
1	Leukemia 11/2007
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2007

Drug/Important Bio-Agent (IBA)

4	Dihydroxyphenylalanine (Dopa)IBA 01/2020 - 09/2015
4	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 03/2008
3	Proteins (Proteins, Gene)FDA Link 10/2019 - 04/2012
3	fluorodopa F 18IBA 08/2016 - 05/2014
3	Biomarkers (Surrogate Marker)IBA 11/2012 - 08/2007
2	CreatineIBA 07/2019 - 12/2015
2	Lactic Acid (Lactate)FDA LinkGeneric 07/2019 - 12/2015
2	N-acetylaspartate (N-acetyl aspartate)IBA 07/2019 - 12/2015
2	Choline (Choline Chloride)IBA 07/2019 - 12/2015
2	Bevacizumab (Avastin)FDA Link 01/2018 - 01/2013
2	Temozolomide (Temodar)FDA LinkGeneric 01/2018 - 05/2014
2	2- (2,6- dimethylmorpholin- 4- yl)- N- (5- (6- morpholin- 4- yl- 4- oxo- 4H- pyran- 2- yl)- 9H- thioxanthen- 2- yl)acetamideIBA 01/2018 - 03/2015
2	Biological ProductsIBA 09/2017 - 09/2016
2	Codon (Codons)IBA 01/2016 - 09/2012
2	Messenger RNA (mRNA)IBA 11/2012 - 05/2011
2	Coloring Agents (Dyes)IBA 05/2011 - 04/2010
1	thiamine triphosphorate (TTP)IBA 06/2022
1	VemurafenibIBA 05/2022
1	Indicators and Reagents (Reagents)IBA 12/2021
1	LipidsIBA 12/2021
1	Lipoproteins (Lipoprotein)IBA 12/2021
1	Growth Hormone (Somatotropin)IBA 01/2021
1	Histones (Histone)IBA 01/2020
1	AntibodiesIBA 01/2020
1	NucleotidesIBA 10/2019
1	U1 small nuclear RNAIBA 10/2019
1	Phosphotransferases (Kinase)IBA 01/2018
1	arginylarginine (Arg-Arg)IBA 01/2016
1	Activin Receptors (Activin Receptor)IBA 11/2015
1	TOR Serine-Threonine KinasesIBA 09/2014
1	Methotrexate (Mexate)FDA LinkGeneric 04/2014
1	Carboplatin (JM8)FDA LinkGeneric 06/2013
1	Etoposide (VP 16)FDA LinkGeneric 06/2013
1	Ifosfamide FDA LinkGeneric 06/2013
1	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2012
1	NucleolinIBA 11/2012
1	ErbB Receptors (EGF Receptor)IBA 11/2012
1	AC133 AntigenIBA 11/2012
1	Cyclin-Dependent Kinase Inhibitor p16IBA 11/2012
1	NADP (NADPH)IBA 09/2012
1	isocitric acid (isocitrate)IBA 09/2012
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 09/2012
1	Histidine (L-Histidine)FDA Link 09/2012
1	Arginine (L-Arginine)FDA Link 09/2012
1	Mitogen-Activated Protein KinasesIBA 04/2012
1	Histocompatibility Antigens Class IIBA 06/2007
1	CalnexinIBA 06/2007
1	HLA Antigens (Human Leukocyte Antigens)IBA 06/2007

Therapy/Procedure

14	Radiotherapy 03/2020 - 04/2004
11	Drug Therapy (Chemotherapy) 01/2020 - 04/2004
10	Therapeutics 12/2021 - 11/2007
3	Salvage Therapy 12/2022 - 08/2006
2	Craniospinal Irradiation 09/2016 - 06/2013
1	Antineoplastic Protocols 12/2021
1	Glycemic Control 12/2021
1	Proton Therapy 03/2019
1	Contraindications 09/2014
1	Second-Look Surgery 09/2011
1	Adjuvant Chemotherapy 09/2011
1	Stem Cell Transplantation 11/2007
1	Maintenance Chemotherapy 11/2007